Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Jul 17
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.
ABSTRACT
.
Related Questions
Would you sequence tumor-specific treatments first? Where would you sequence non-targeted standard chemotherapy or immunotherapy?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (October 11, 2025)
Non-small cell lung cancer (NSCLC) can harbor different HER2 alterations: HER2 protein overexpression (2-35%), HER2 gene amplification (2-20%), and HER2 gene mutations (1-4%)....